Psychedelics re-engineered for potential use in the clinic.

The authors of this free full-text commentary write about Cameron et al's recent paper "A non-hallucinogenic psychedelic analogue with therapeutic potential." The commentary is informative & helpful, stating - "An analogue of the psychedelic drug ibogaine has been developed. The analogue mirrors ibogaine’s ability to treat addiction and depression in animal models, has fewer side effects and is much simpler to synthesize."

Previous
Previous

It Takes Guts: Psychedelic Treatment Approaches to Autoimmune Disorders

Next
Next

2019: A year of expansion in psychedelic research, industry, and deregulation.